AFATINIB

作品数：25被引量：53H指数：4
导出分析报告
相关领域：医药卫生更多>>
相关作者：李国锋宋勇王允芬范方田王立芳更多>>
相关机构：南方医科大学南方医科大学南方医院中山大学南京医科大学更多>>
相关期刊：《Chinese Journal of Polymer Science》《国外药讯》《中华肿瘤杂志》《World Journal of Clinical Cases》更多>>
相关基金：国家自然科学基金江苏省自然科学基金国家重点基础研究发展计划广东省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Non small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor response when treated with afatinib: a case report
《Frontiers of Medicine》2025年第1期170-173,共4页Xiaotong Qiu Liangkun You Chongwei Wang Jin Sheng 
SMARCA4-deficient non small cell lung cancer (SMARCA4-dNSCLC) has recently garnered increasing attention due to its high malignancy and poor prognosis. The literature suggests that in non small cell lung cancer (NSCLC...
关键词：SMARCA4-dNSCLC rare EGFR mutations targeted therapy case report 
Clinical efficacy and identification of factors confer resistance to afatinib(tyrosine kinase inhibitor)in EGFR-overexpressing esophageal squamous cell carcinoma被引量：2
《Signal Transduction and Targeted Therapy》2024年第7期3130-3140,共11页Yanni Wang Chang Liu Huan Chen Xi Jiao Yujiao Wang Yanshuo Cao Jian Li Xiaotian Zhang Yu Sun Na Zhuo Fengxiao Dong Mengting Gao Fengyuan Wang Liyuan Dong Jifang Gong Tianqi Sun Wei Zhu Henghui Zhang Lin Shen Zhihao Lu 
supported by the National Natural Science Foundation of China(No.92159106,82073230);the National Youth Top-Level Talent Support Program(“Ten Thousand Talents Scheme”)(12Y4962).
Epidermal growth factor receptor(EGFR)is reportedly overexpressed in most esophageal squamous cell carcinoma(ESCC)patients,but anti-EGFR treatments offer limited survival benefits.Our preclinical data showed the promi...
关键词：ESOPHAGEAL SQUAMOUS EXPRESSING 
EGFR-mutant non-small cell lung cancer patients harboring CDK4 amplification show favorable response to afatinib:Two case reports
《Chinese Medical Journal》2024年第12期1465-1467,共3页Shuting Zhan Bo Cheng Xiwen Liu Jianfu Li Ge Bai Qi Cai Huiting Wang Yang Xiang Chunyan Li Jianxing He Wenhua Liang 
supported by grants from China National Science Foundation(Nos.82022048 and 82373121);the Science and Technology Planning Project of Guangzhou(No.202206080013);the National Key Research&Development Program(No.2022YFC2505100)
To the Editor:Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)show significant efficacy in patients with advanced-stage non-small cell lung cancer(NSCLC)with sensitive EGFR mutations and signific...
关键词：CDK4 NSCLC EGFR 
Glucocorticoid reduces the efficacy of afatinib on the head and neck squamous cell carcinoma
《BIOCELL》2023年第2期329-338,共10页DONGYANG WANG YI CHEN JING HUANG YOU ZHANG CHONGKUI SUN YINGQIANG SHEN 
supported by the Research Funding(No.RCDWJS 2020-20);Research and Development Program(RD-02-202002)from West China School/Hospital of Stomatology Sichuan University;the Natural Science Foundation of China(81902784&81872207);Sichuan Provincial Fund of China(2022YFSY0058).
Glucocorticoids(GC)are widely used to counter the adverse events during cancer therapy;nonetheless,previous studies pointed out that GC may reduce the efficacy of chemotherapy on cancer cells,especially in epidermal g...
关键词：GLUCOCORTICOID Head and neck squamous cell carcinoma AFATINIB EGFR Targeted therapy MTOR 
GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib被引量：3
《Acta Pharmacologica Sinica》2022年第6期1534-1543,共10页Le-ying Chen Qing You Da-zhao Lv Shuai-hu Li Shi-yi Zhang 
This work was,in part,supported by the Youth Thousand Talents Program of China,start-up grants from the Shanghai Jiao Tong University(WF220408211);This work was also supported by the grants from the State Key Laboratory of Onco-genes and Related Genes(90-17-02);from the Interdisciplinary Program of Shanghai Jiao Tong University(YG2017MS18).
Many G-protein-coupled receptor(GPCR)agonists have been studied for transactivating epidermal growth factor receptor(EGFR)signaling through extracellular or intracellular pathways.Accumulated evidence has confirmed th...
关键词：GPCR agonist EGFR transactivation EGFR inhibitor RASH 
Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive non-small-cell lung cancer:A case report
《World Journal of Clinical Cases》2022年第6期1883-1888,共6页Bin-Bin Shan Yuan Li Chang Zhao Xiao-Qin An Quan-Mao Zhang 
BACKGROUND Insertions in exon 19 in the epidermal growth factor receptor gene(EGFR)is a rarely seen mutation in non-small cell lung cancer.These patients have been effectively treated with sequential EGFR tyrosine kin...
关键词：Non-small cell lung cancer Next-generation sequencing EGFR exon 19 insertion AFATINIB Case report 
Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report
《World Journal of Clinical Cases》2021年第27期8220-8225,共6页Yao Zhang Ji-Qiao Shen Lin Shao Yan Chen Lei Lei Jia-Lei Wang 
BACKGROUND Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)have been adopted as the standard of care for non-small cell lung cancer(NSCLC)patients harboring EGFR sensitizing mutations.Besides the...
关键词：AFATINIB Osimertinib Epidermal growth factor receptor L861Q-L833F Nonsmall cell lung cancer Case report 
Cost-effectiveness analysis of tyrosine kinase inhibitors(erlotinib,gefitinib,afatinib and osimertinib)as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer被引量：6
《Journal of Chinese Pharmaceutical Sciences》2021年第3期253-263,共11页Shaohong Luo Liangliang Dong Yiyuan Li Dan Xu Min Chen 
Gefitinib,erlotinib,afatinib and osimertinib have been recommended as the first-line treatment for epidermal growth factor receptor(EGFR)-mutated advanced non-small cell lung cancer(NSCLC),whereas no studies have comp...
关键词：Cost-effectiveness analysis Markov model Tyrosine kinase inhibitor Non-small cell lung cancer First-line therapy Epidermal growth factor receptor 
Efficacy of afatinib in a patient with rare EGFR(G724S/R776H)mutations and amplification in lung adenocarcinoma:A case report被引量：1
《World Journal of Clinical Cases》2021年第6期1329-1335,共7页Shu-Yan He Qing-Feng Lin Jie Chen Gui-Ping Yu Jun-Ling Zhang Dong Shen 
BACKGROUND The most common EGFR mutations are in-frame deletions in exon 19 and point mutations in exon 21.Cases with classical EGFR mutations show a good response to EGFR tyrosine kinase inhibitors(TKIs),the standard...
关键词：EGFR G724S and R776H AFATINIB Non-small cell lung cancer Case report 
Co-delivery of Doxorubicin and Afatinib with pH-responsive Polymeric Nanovesicle for Enhanced Lung Cancer Therapy被引量：4
《Chinese Journal of Polymer Science》2019年第12期1224-1233,I0006,共11页Heng-Ye Gong Yan-Gui Chen Xing-Su Yu Hong Xiao Jin-Peng Xiao Yong Wang Xin-Tao Shuai 
financially supported by the National Basic Research Program of China (No. 2015CB755500);the Natural Science Foundation of Guangdong Province (No. 2014A030312018);Science and Technology Planning Project of Guangdong Province (No. 2016A020215088)
Drug-resistance and drastic side effects are two major issues of traditional chemotherapy which may result in trail failure even death.Nanoparticle-mediated multidrug combination treatment has been proven to be a feas...
关键词：NANOVESICLE Polymeric vector Combination THERAPY PH-RESPONSIVE 
全选清除导出
共3页<123>
检索报告 对象比较 聚类工具 使用帮助 返回顶部